In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232

2013/08/24 by Eric D. Hostetler, Aniket Joshi, Aniket D. Joshi +36 · 26 citations
Medicine · Neuroscience · #Migraine and Headache Studies #Trigeminal Neuralgia and Treatments #Neuropeptides and Animal Physiology

paper · doi:10.1124/jpet.113.206458

Cited by

• Advances in CGRP therapeutic targets for migraine: where do we stand 5 years later?
• Dural administration of inflammatory soup or Complete Freund's Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion. [europepmc]
• Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage. [europepmc]
• Characterization of a mouse model of headache. [europepmc]
• Efficacy of ( S )-Lacosamide in preclinical models of cephalic pain. [europepmc]
• Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. [europepmc]
• Non-invasive methods for measuring vascular changes in neurovascular headaches. [europepmc]
• A critical evaluation of validity and utility of translational imaging in pain and analgesia: Utilizing functional imaging to enhance the process. [europepmc]
• Effect of a calcitonin gene-related peptide-binding L-RNA aptamer on neuronal activity in the rat spinal trigeminal nucleus. [europepmc]
• Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy. [europepmc]
• CGRP and the Trigeminal System in Migraine. [europepmc]
• Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. [europepmc]
• Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. [europepmc]
• Discovery of the Migraine Prevention Therapeutic Aimovig (Erenumab), the First FDA-Approved Antibody against a G-Protein-Coupled Receptor. [europepmc]
• Lasmiditan mechanism of action - review of a selective 5-HT 1F agonist. [europepmc]
• Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor. [europepmc]
• Brain barriers and their potential role in migraine pathophysiology. [europepmc]
• Schwann cell endosome CGRP signals elicit periorbital mechanical allodynia in mice. [europepmc]
• CGRP Administration Into the Cerebellum Evokes Light Aversion, Tactile Hypersensitivity, and Nociceptive Squint in Mice. [europepmc]
• Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Migraine Pathogenesis. [europepmc]
• Involvement of the cerebellum in migraine. [europepmc]
• Characterization of Antibodies against Receptor Activity-Modifying Protein 1 (RAMP1): A Cautionary Tale. [europepmc]
• Shared and independent roles of CGRP and PACAP in migraine pathophysiology. [europepmc]
• Mode and site of action of therapies targeting CGRP signaling. [europepmc]
• Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: A prospective cohort study. [europepmc]
• Effect of anti-CGRP-targeted therapy on migraine aura: Results of an observational case series study. [europepmc]